Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences names Damasio as finance chief as it travels towards profitability

Most recently, he was finance director at Nelipak Packaging, a private equity backed medical packaging manufacturer
Pressure Biosciences names Damasio as finance chief as it travels towards profitability
Experienced financial executive Damasio is back at the firm

Pressure Biosciences Inc (OTCQB:PBIO) has welcomed Joseph L Damasio back to the company as it ramps up, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

Most recently, the experienced executive was finance director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over $100mln in annual global sales.

Damasio told investors on Monday: "The company has developed and is beginning to implement a comprehensive fiscal plan that we believe is both achievable and sustainable, while supporting continued growth.

"Among its many goals, the plan calls for an up-list to the NASDAQ stock market, the addition of personnel in key areas, a strong focus in and expansion of sales and marketing, and a march towards profitability."

Pressure's president and chief executive Richard T. Schumacher added : "We are delighted to have Joe re-join the senior management team at PBI.

"During his five years away, Joe gained a wealth of knowledge and experience that we believe will help us significantly as we look to accelerate the company's growth on our path to profitability and long-term success. Welcome back, Joe."

Last month, the group bolstered its marketing and sales capabilities by contracting a well-regarded life sciences lead generation service and hiring two of four new field sales directors.

EKG Sales Associates (EKG) has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers.

As well as engaging EKG, PBI has also hired Ms Rajni Kareer who will be the sales director covering all of the west coast of the US.

The other new director, Nicholas Cobb, will cover upstate New York, northern New England, and all of eastern Canada.

Shares shed over 4% to US$0.31.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1511808112_surgeon.jpg
November 27 2017
In a letter to stakeholders, George Adams, the president and chief executive, highlighted that the device would "reduce the cost of its equipment significantly"
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use